Walker Karin L.'s most recent trade in Prothena Corporation plc was a trade of 70,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on March 5, 2025.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Prothena Corporation plc
|
Karin L. Walker | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2025 | 70,000 | 70,000 | - | - | Stock Option (Right to Buy) | |
Prothena Corporation plc
|
L. Walker Karin | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 54,000 | 54,000 | - | - | Stock Option (Right to Buy) | |
Prothena Corporation plc
|
Walker L. Karin | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jan 2024 | 5,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
Prothena Corporation plc
|
Karin Walker L. | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.53 per share. | 24 Jan 2024 | 5,000 | 5,000 (0%) | 0% | 13.5 | 67,650 | Ordinary Shares, par value $0.01 per share |
Prothena Corporation plc
|
Karin L. Walker | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 34.00 per share. | 24 Jan 2024 | 5,000 | 0 (0%) | 0% | 34 | 170,000 | Ordinary Shares, par value $0.01 per share |
Prothena Corporation plc
|
L. Karin Walker | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Dec 2023 | 5,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
Prothena Corporation plc
|
Walker L. Karin | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.53 per share. | 20 Dec 2023 | 5,000 | 5,000 (0%) | 0% | 13.5 | 67,650 | Ordinary Shares, par value $0.01 per share |
Prothena Corporation plc
|
Walker L. Karin | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 37.45 per share. | 20 Dec 2023 | 3,322 | 0 (0%) | 0% | 37.5 | 124,409 | Ordinary Shares, par value $0.01 per share |
Prothena Corporation plc
|
Walker Karin L. | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 36.68 per share. | 20 Dec 2023 | 1,678 | 3,322 (0%) | 0% | 36.7 | 61,543 | Ordinary Shares, par value $0.01 per share |
Prothena Corporation plc
|
Karin L. Walker | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jul 2023 | 5,000 | 10,481 | - | - | Stock Option (right to buy) | |
Prothena Corporation plc
|
Karin L. Walker | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.04 per share. | 19 Jul 2023 | 5,000 | 5,000 (0%) | 0% | 15.0 | 75,200 | Ordinary Shares, par value $0.01 per share |
Prothena Corporation plc
|
Karin L. Walker | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 68.96 per share. | 19 Jul 2023 | 3,966 | 1,034 (0%) | 0% | 69.0 | 273,484 | Ordinary Shares, par value $0.01 per share |
Prothena Corporation plc
|
Karin L. Walker | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 70.08 per share. | 19 Jul 2023 | 1,034 | 0 (0%) | 0% | 70.1 | 72,459 | Ordinary Shares, par value $0.01 per share |
Cyclacel Pharmaceuticals Inc
|
Karin L. Walker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2023 | 42,438 | 42,438 | - | - | Stock Option (right to buy) | |
Cyclacel Pharmaceuticals Inc
|
Karin L. Walker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2023 | 21,219 | 40,602 (0%) | 0% | 0 | Common Stock | |
Prothena Corporation plc
|
Karin L. Walker | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jun 2023 | 5,000 | 15,481 | - | - | Stock Option (right to buy) | |
Prothena Corporation plc
|
Karin L. Walker | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.04 per share. | 20 Jun 2023 | 5,000 | 5,000 (0%) | 0% | 15.0 | 75,200 | Ordinary Shares, par value $0.01 per share |
Prothena Corporation plc
|
Karin L. Walker | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 69.49 per share. | 20 Jun 2023 | 2,471 | 529 (0%) | 0% | 69.5 | 171,699 | Ordinary Shares, par value $0.01 per share |
Prothena Corporation plc
|
Karin L. Walker | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 67.88 per share. | 20 Jun 2023 | 2,000 | 3,000 (0%) | 0% | 67.9 | 135,768 | Ordinary Shares, par value $0.01 per share |
Prothena Corporation plc
|
Karin L. Walker | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 69.99 per share. | 20 Jun 2023 | 529 | 0 (0%) | 0% | 70.0 | 37,027 | Ordinary Shares, par value $0.01 per share |
Prothena Corporation plc
|
Karin L. Walker | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.04 per share. | 19 May 2023 | 5,000 | 5,000 (0%) | 0% | 15.0 | 75,200 | Ordinary Shares, par value $0.01 per share |
Prothena Corporation plc
|
Karin L. Walker | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 May 2023 | 5,000 | 20,481 | - | - | Stock Option (right to buy) | |
Prothena Corporation plc
|
Karin L. Walker | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 73.63 per share. | 19 May 2023 | 2,823 | 2,177 (0%) | 0% | 73.6 | 207,850 | Ordinary Shares, par value $0.01 per share |
Prothena Corporation plc
|
Karin L. Walker | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 74.47 per share. | 19 May 2023 | 2,177 | 0 (0%) | 0% | 74.5 | 162,128 | Ordinary Shares, par value $0.01 per share |
Prothena Corporation plc
|
Karin L. Walker | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Apr 2023 | 5,000 | 25,481 | - | - | Stock Option (right to buy) | |
Prothena Corporation plc
|
Karin L. Walker | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.04 per share. | 19 Apr 2023 | 5,000 | 5,000 (0%) | 0% | 15.0 | 75,200 | Ordinary Shares, par value $0.01 per share |
Prothena Corporation plc
|
Karin L. Walker | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 52.64 per share. | 19 Apr 2023 | 2,917 | 2,083 (0%) | 0% | 52.6 | 153,563 | Ordinary Shares, par value $0.01 per share |
Prothena Corporation plc
|
Karin L. Walker | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 53.25 per share. | 19 Apr 2023 | 2,083 | 0 (0%) | 0% | 53.2 | 110,917 | Ordinary Shares, par value $0.01 per share |
Prothena Corporation plc
|
Karin L. Walker | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.04 per share. | 20 Mar 2023 | 5,000 | 5,000 (0%) | 0% | 15.0 | 75,200 | Ordinary Shares, par value $0.01 per share |
Prothena Corporation plc
|
Karin L. Walker | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Mar 2023 | 5,000 | 30,481 | - | - | Stock Option (right to buy) | |
Prothena Corporation plc
|
Karin L. Walker | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 47.51 per share. | 20 Mar 2023 | 3,903 | 1,097 (0%) | 0% | 47.5 | 185,443 | Ordinary Shares, par value $0.01 per share |
Prothena Corporation plc
|
Karin L. Walker | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 48.46 per share. | 20 Mar 2023 | 1,097 | 0 (0%) | 0% | 48.5 | 53,166 | Ordinary Shares, par value $0.01 per share |
Prothena Corporation plc
|
Karin L. Walker | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2023 | 20,000 | 53,481 | - | - | Stock Option (right to buy) | |
Prothena Corporation plc
|
Karin L. Walker | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.04 per share. | 15 Mar 2023 | 20,000 | 20,000 (0%) | 0% | 15.0 | 300,800 | Ordinary Shares, par value $0.01 per share |
Prothena Corporation plc
|
Karin L. Walker | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 48.66 per share. | 15 Mar 2023 | 10,569 | 0 (0%) | 0% | 48.7 | 514,332 | Ordinary Shares, par value $0.01 per share |
Prothena Corporation plc
|
Karin L. Walker | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 48.14 per share. | 15 Mar 2023 | 9,431 | 10,569 (0%) | 0% | 48.1 | 454,014 | Ordinary Shares, par value $0.01 per share |
Prothena Corporation plc
|
Karin L. Walker | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 38,000 | 38,000 | - | - | Stock Option (Right to Buy) | |
Prothena Corporation plc
|
Karin L. Walker | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.04 per share. | 24 Oct 2022 | 20,000 | 20,000 (0%) | 0% | 15.0 | 300,800 | Ordinary Shares, par value $0.01 per share |
Prothena Corporation plc
|
Karin L. Walker | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Oct 2022 | 20,000 | 65,481 | - | - | Stock Option (right to buy) | |
Prothena Corporation plc
|
Karin L. Walker | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 56.39 per share. | 24 Oct 2022 | 7,907 | 12,093 (0%) | 0% | 56.4 | 445,868 | Ordinary Shares, par value $0.01 per share |
Prothena Corporation plc
|
Karin L. Walker | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 57.34 per share. | 24 Oct 2022 | 7,144 | 4,949 (0%) | 0% | 57.3 | 409,603 | Ordinary Shares, par value $0.01 per share |
Prothena Corporation plc
|
Karin L. Walker | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 58.25 per share. | 24 Oct 2022 | 3,785 | 1,164 (0%) | 0% | 58.3 | 220,489 | Ordinary Shares, par value $0.01 per share |
Prothena Corporation plc
|
Karin L. Walker | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 58.98 per share. | 24 Oct 2022 | 1,164 | 0 (0%) | 0% | 59.0 | 68,653 | Ordinary Shares, par value $0.01 per share |
Cyclacel Pharmaceuticals Inc
|
Karin L. Walker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2022 | 31,645 | 31,645 | - | - | Stock Option (right to buy) | |
Cyclacel Pharmaceuticals Inc
|
Karin L. Walker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2022 | 15,822 | 19,383 (0%) | 0% | 0 | Common Stock | |
Cyclacel Pharmaceuticals Inc
|
Karin L. Walker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2021 | 4,748 | 7,122 | - | - | Stock Option (right to buy) | |
Cyclacel Pharmaceuticals Inc
|
Karin L. Walker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2021 | 2,374 | 3,561 (0%) | 0% | 0 | Common Stock | |
Cyclacel Pharmaceuticals Inc
|
Karin L. Walker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2021 | 2,374 | 7,122 | - | - | Stock Option (right to buy) | |
Cyclacel Pharmaceuticals Inc
|
Karin L. Walker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2021 | 1,187 | 3,561 (0%) | 0% | 0 | Common Stock | |
Prothena Corporation plc
|
Karin L. Walker | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 28,000 | 28,000 | - | - | Employee Stock Option (Right to Buy) | |
Prothena Corporation plc
|
Karin L. Walker | Chief Accounting Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 12 Feb 2021 | 30,000 | 0 | - | - | Employee Stock Option (Right to Buy) | |
Prothena Corporation plc
|
Karin L. Walker | Chief Accounting Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 12 Feb 2021 | 25,000 | 0 | - | - | Employee Stock Option (Right to Buy) | |
Prothena Corporation plc
|
Karin L. Walker | Chief Accounting Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 12 Feb 2021 | 25,000 | 0 | - | - | Employee Stock Option (Right to Buy) | |
Prothena Corporation plc
|
Karin L. Walker | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2021 | 18,796 | 18,796 | - | - | Employee Stock Option (Right to Buy) | |
Prothena Corporation plc
|
Karin L. Walker | Chief Accounting Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 12 Feb 2021 | 17,500 | 0 | - | - | Employee Stock Option (Right to Buy) | |
Prothena Corporation plc
|
Karin L. Walker | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2021 | 15,909 | 15,909 | - | - | Employee Stock Option (Right to Buy) | |
Prothena Corporation plc
|
Karin L. Walker | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2021 | 15,625 | 15,625 | - | - | Employee Stock Option (Right to Buy) | |
Prothena Corporation plc
|
Karin L. Walker | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2021 | 15,625 | 15,625 | - | - | Employee Stock Option (Right to Buy) | |
Cyclacel Pharmaceuticals Inc
|
Karin L. Walker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Nov 2020 | 5,200 | 5,200 | - | - | Stock Option (right to buy) |